HLA class I antigen down-regulation in primary ovary carcinoma lesions: Association with disease stage

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 67-72

  Vitale, Marco ^a,b   Pelusi, Giuseppe ^c   Taroni, Beatrice ^c   Gobbi, Giuliana ^a   Micheloni, Cristina ^a   Rezzani, Rita ^d   Donato, Francesco ^d   Wang, Xinhui ^e   Ferrone, Soldano ^e  

^a UNIVERSITY OF PARMA   (Italy)

^b Unit of Bologna   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER RISK; CLINICAL ARTICLE; DISEASE COURSE; DOWN REGULATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; OVARY ADENOCARCINOMA; OVARY FOLLICLE CELL; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OVARIAN NEOPLASMS; OVARY; PHENOTYPE; TIME FACTORS;

EID: 11344290086     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002;2:514-20.
3. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003;73:3-29.
4. Schreiber H. Tumor immunology. In: Paul ED, editor. Fundamental Immunology. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 1557-92.
5. York IA, Goldberg AL, Mo XY, Rock KL. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 1999;172:49-66.
6. Lankat-Buttgereit B, Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 2002;82:187-204.
7. Bouvier M. Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective. Mol Immunol 2003;39:697-706.
8. Momburg F, Tan P. Tapasin: the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol Immunol 2002;39:217-33.
9. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21:455-64.
10. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995;55:5191-4.
11. Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998;58:737-42.
12. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001;61:8647-50.
13. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
14. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994;145:505-9.
15. Le YS, Kim TE, Kim BK, et al. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 2002;34:18-26.
16. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
17. Odicino F, Favalli G, Zigliani L, Pecorelli S. Staging of gynecologic malignancies. Surg Clin North Am 2001;81:753-70.
18. Hicklin DJ, Kageshita T, Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens 1996;48:38-46.
19. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
20. Agresti A. In: Categorical data analysis. New York: John Wiley and Sons; 1992.
21. Agresti A. In: Analysis of ordinal categorical data. New York: John Wiley and Sons; 1984.
22. Dixon WJ, Brown MB, Engelman L, Jennrich NI. In: BMDP Statistical Software Manual. Los Angeles (CA): University of California Press; 1993.
23. Squire R, Fowler CL, Brooks SP, Rich GA, Cooney DR. The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma. J Pediatr Surg 1990;25:381-6.
24. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 2000;6:2794-802.
25. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996;73:148-53.
26. Kallfelz M, Jung D, Hilmes C, et al. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. Int J Cancer 1999;81:125-33.
27. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
28. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999;5:178-86.